• Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study

  NCT05281770

  Unknown statusObservationalUpdated Oct 20, 2022
• CGRP Inhibition, Autonomic Function, and Migraine

  NCT04628429

  RecruitingObservationalUpdated Dec 10, 2024
• Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies

  NCT06459648

  RecruitingObservationalUpdated Jul 2, 2026
• The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients

  NCT04452929

  Unknown statusInterventionalNot ApplicableUpdated Oct 8, 2020
• A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications

  NCT06701526

  Active, not recruitingInterventionalPhase 4Updated May 13, 2026
• Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab

  NCT04592952

  Unknown statusInterventionalPhase 4Updated Oct 24, 2022

ClinicalTrials.gov ID

NCT07159750

Lead Sponsor

Hospital Universitari Vall d'Hebron Research InstituteOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

700Estimated

Last Update Posted

Sep 8, 2025Actual

Start Date

Jan 2, 2024Actual

Primary Completion Date

Jan 2026Estimated

Completion Date

Jan 2026Estimated

Official Title

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

Brief Summary

The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.

Detailed Description

It is a 2-year, multicenter observational study. Patients who meet reimbursement criteria according to local regulations and willing to participate in the study will be included. Monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) will be started and baseline assessment will be conducted. There will be visits every 6 months to assess effectiveness, side-effects, PROMs, and elegibility to continue with the study drug. The observation of patients will last 2 years.

• Migraine
• Episodic Migraine
• Chronic Migraine, Headache

• CGRP antibody or gepant

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Migraine diagnosis according to ICHD-III.
• Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations.
• Signature of informed consent.

Exclusion Criteria:

• Presence of headache different from migraine.
• Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Hospital Universitari Vall d'Hebron Research InstituteOTHER

hernandez.natalia12@gmail.com(+57) 304 6452119